Anti-Rheumatic Drugs - ASEAN

ASEAN

The revenue in the Anti-Rheumatic Drugs market is estimated to reach US$0.31bn in 2024.
It is predicted that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of 1.86%, leading to a market volume of US$0.34bn by 2029.
When compared globally, United States is expected to generate the highest revenue, amounting to US$34,700.00m in 2024.
ASEAN countries, such as Indonesia and Thailand, are experiencing a growing demand for anti-rheumatic drugs due to an aging population and increasing prevalence of rheumatic diseases.

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Rheumatic Drugs in ASEAN has been increasing steadily in recent years.

Customer preferences: Patients in ASEAN countries are increasingly seeking medical attention for rheumatoid arthritis and other autoimmune diseases. This has led to an increase in demand for Anti-Rheumatic Drugs in the region. Patients are also becoming more aware of the importance of early diagnosis and treatment of these conditions, which is driving demand for these drugs.

Trends in the market: The Anti-Rheumatic Drugs market in ASEAN is largely dominated by multinational pharmaceutical companies. These companies are investing heavily in research and development of new drugs to treat rheumatoid arthritis and other autoimmune diseases. The market is also witnessing an increase in the availability of biosimilars, which are cheaper alternatives to branded drugs. This is driving down the cost of treatment and making it more accessible to patients.

Local special circumstances: The ASEAN region is diverse, with different countries having different healthcare systems and regulations. This can affect the availability and accessibility of Anti-Rheumatic Drugs in different countries. For example, in some countries, these drugs may only be available in major cities, while in others, they may only be available in private hospitals. This can make it difficult for patients in rural areas to access these drugs.

Underlying macroeconomic factors: The ASEAN region is experiencing rapid economic growth, which is driving demand for healthcare services. As the population ages, the prevalence of rheumatoid arthritis and other autoimmune diseases is expected to increase, which will further drive demand for Anti-Rheumatic Drugs. Additionally, the increasing availability of healthcare insurance is making these drugs more affordable to patients.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.